SUBSCRIBE
SUBSCRIBE

Nick Paul Taylor

Nick is a freelance writer who has been reporting on the global life sciences industry since 2008. With a BSc in biology, Nick writes about the science and business of biopharma and medtech for numerous healthcare publications. He can be reached at nick.paul.taylor@gmail.com or on LinkedIn.

A teamwork with different purpose. Isolated Vector illustration
Drug Development
BioNTech’s Multi-Modality Play Outpaces Moderna’s mRNA-Focused Pipeline
After advancing in lockstep through the pandemic, the fortunes of the biotechs have diverged as their use of COVID-19 windfalls has taken shape.
February 3, 2026
 · 
5 min read
 · 
Nick Paul Taylor
Businessman pushing boulder uphill vector concept of Sisyphus. Symbol of hard work, futile effort, strength, struggle, challenge but also motivation and ambition. Eps10 vector illustration.
Manufacturing
As Amgen and Lilly Recommit, Puerto Rico Seeks To Regain Manufacturing Momentum
After suffering in the wake of expired tax incentives for pharmas, the island is trying to take advantage of geopolitics to grow its drug manufacturing sector.
February 3, 2026
 · 
4 min read
 · 
Nick Paul Taylor
Welcome to Pennsylvania sign at the Pennsylvania/New York state line along Interstate 90.
Manufacturing
Eli Lilly Commits $3.5B To Build Injectable Obesity Drug Plant in PA
The facility, which is part of Lilly’s $50 billion reshoring drive, will make obesity drugs such as tirzepatide and retatrutide when it starts operations in 2031.
February 2, 2026
 · 
2 min read
 · 
Nick Paul Taylor
Crowdfunding concept with money icon and human hands in retro 80s collage mixed media vector illustration. Idea for financing business project, funding, philanthropy, cooperation, bank credit and startup development.
Manufacturing
BMS-Partnered Cellares Raises $257M for Cell Therapy Manufacturing Expansion
Cellares, which last year became the first company to receive the FDA’s new advanced manufacturing technology designation, expects to support clinical production this year and offer commercial-scale manufacturing services in 2027.
January 28, 2026
 · 
2 min read
 · 
Nick Paul Taylor
Creative sketch collage of business people handshake gesture approval project development success colleagues cooperation support.
Manufacturing
Big Pharma Tight-Lipped on Details of API Stockpile Deals
Bristol Myers Squibb, GSK and Merck are contributing drug ingredients as part of their deals with the White House but are keeping many of the terms of their agreements private.
January 27, 2026
 · 
4 min read
 · 
Nick Paul Taylor
Business and Project Roadmap Concept. Touching on virtual screen with roadmap overlay representing steps in a project or strategic planning process. Waypoint icons and ends with goal achievement.
Manufacturing
FDA Sets Feb. 1 Launch Date for PreCheck Pilot To Strengthen Domestic Supply Chain
The U.S. regulator shared the roadmap for implementing the program, first proposed in August 2025, and teased changes made in response to industry feedback.
January 22, 2026
 · 
2 min read
 · 
Nick Paul Taylor
Dec 3, 2019 South San Francisco / CA / USA - Genentech headquarters in San Francisco Bay Area; Genentech, Inc., is an American biotechnology corporation which became a subsidiary of Roche in 2009
Manufacturing
Roche Raises NC Manufacturing Investment to $2B To Support Obesity Challenge
Genentech, a member of the Roche Group, plans to open the facility in 2029 to ramp up capacity to make obesity candidates, including the dual GLP-1/GIP receptor agonist CT-388.
January 21, 2026
 · 
2 min read
 · 
Nick Paul Taylor
Photo taken in Ting Kok, Hong Kong
Manufacturing
CDMOs Pin Hopes for Accelerating Uptake at New US Sites on FDA’s PreCheck Program
The initiative could tackle the first-mover disadvantage some CDMOs believe deters early customers, but leaders at companies including Novo Nordisk see hurdles to implementing the changes.
January 20, 2026
 · 
4 min read
 · 
Nick Paul Taylor
Corporate headquarters of Novo Nordisk in Denmark
Business
JPM26: Novo Refocuses on Diabetes and Obesity Amid Push To Expand GLP-1 Market
After a period of diversification, Novo Nordisk is returning to its roots by focusing on the 2 billion people with diabetes, obesity or overweight.
January 14, 2026
 · 
3 min read
 · 
Nick Paul Taylor
Pictured: Eli Lilly's headquarters in Indianapolis
Business
JPM26: Lilly Plots Path to Dominance as Obesity Market Enters a New Era
BMO analysts say Eli Lilly is well-positioned to maintain its lead in the ballooning weight loss space, predicting “strengthening leadership in obesity and beyond” as portfolios expand and patient access improves.
January 14, 2026
 · 
2 min read
 · 
Nick Paul Taylor
Johnson & Johnson's business center in Switzerland
Manufacturing
J&J To Add 500 Jobs at New Plant, Doubling Down on North Carolina
Johnson & Johnson’s second facility in Wilson, North Carolina, is part of a $55 billion push to make all advanced medicines used in the U.S. domestically.
January 13, 2026
 · 
2 min read
 · 
Nick Paul Taylor
Manhattan, New York USA - July 9, 2011: Pfizer letter sign on the building's Headquarters. Pfizer's is the largest pharmaceutical company in the world.
Business
JPM26: Pfizer Fast-Tracks Obesity Programs in Race Against Patent Cliff
Facing the loss of exclusivity on key products, Pfizer has pulled forward its lead obesity asset into Phase III and targeted a 2028 launch. CEO Albert Bourla explained the pharma’s strategy at J.P. Morgan on Monday.
January 13, 2026
 · 
3 min read
 · 
Nick Paul Taylor
FDA signage at its headquarters in Maryland
Manufacturing
AbbVie, Amgen, Lilly Lead Calls for FDA To Update Post-Approval Change Rules
Drugmakers told the FDA that inflexible post-approval change requirements are among the top regulatory barriers to the reshoring of pharmaceutical manufacturing.
January 13, 2026
 · 
5 min read
 · 
Nick Paul Taylor
AbbVie's office in South San Francisco, California
Cancer
AbbVie Bets Nearly $5B on RemeGen To Vie for Position in Hot Bispecific Market
The deal, which sees AbbVie paying RemeGen $650 million upfront, gives the pharma ex-China rights to the biotech’s PD-1/VEGF bispecific antibody—a modality being targeted by companies including BMS, Merck and Pfizer.
January 12, 2026
 · 
2 min read
 · 
Nick Paul Taylor
Cambridge, USA - 16 August 2024. View of Moderna office entrance with logo sign, Biotechnology industry
Business
Moderna Hits 2025 Revenue Goal as Operating Costs Fall Faster than Forecast
While Moderna’s full-year sales landed in the upper end of its target range, Jefferies analysts said further reductions are needed if the biotech hopes to hit its 2028 break-even target.
January 12, 2026
 · 
2 min read
 · 
Nick Paul Taylor
Load More